1. Raynaud's Syndrome: Peripheral Vasospasm
Raynaud's phenomenon (RP) affects 3–5% of the population, predominantly women (F:M ratio = 9:1):
- Excessive vasospasm in cold or anxiety-<a%20href=" https:>cortisol-natural-relief">stress → ischemia of fingers/toes (pale, blue, red)
- Endothelial dysfunction: reduced NO production → less basal vasodilation
- TXA2 excess: thromboxane A2 from platelets → additional vasoconstriction
- TRPV1 hypersensitization: cold-sensitive channels in perivascular fibers → disproportionate cold response
- Secondary RP: linked to scleroderma, ginger lupus → damaged endothelium
2. Ginger Mechanisms in Raynaud's
2.1 TRPV1 → CGRP (Potent Vasodilation)
Gingerols activate TRPV1 in perivascular C-fibers → CGRP release (calcitonin gene-related peptide) → direct relaxation of digital arterioles → increased blood flow. Measurable: +1.2–1.8°C finger temperature via infrared thermography within 45 min.
2.2 TXA2 Inhibition
6-Gingerol inhibits thromboxane synthase + COX-1 in platelets: TXA2 −40–55% → less vasoconstriction in cold. PGI2 (prostacyclin) vasodilator relatively favored.
2.3 Improved Blood Fluidity
Sugar-free ginger shot reduces erythrocyte viscosity and platelet aggregation → improved rheology in digital capillaries → less prolonged ischemia during attacks.
2.4 Endothelial Protection (Nrf2/NO)
Nrf2/HO-1 activation → reduction of endothelial oxidative stress → better basal NO production → more balanced vascular tone.
3. Comparison: Ginger vs. Other Approaches in Raynaud's
| Approach | Mechanism | TRPV1/CGRP | Anti-TXA2 | Endothelial Protection |
|---|---|---|---|---|
| Ginger (INTI) | TRPV1, TXA2, Nrf2 | ✅ Strong | ✅ −40–55% | ✅ Nrf2/NO |
| Ginkgo biloba | PAF, viscosity | ❌ No | ✅ Partial | ✅ Partial |
| Omega-3 | TXA2, IL-6 | ❌ No | ✅ Moderate | ✅ Moderate |
| L-arginine | NO synthesis | ❌ No | ❌ No | ✅ NO direct |
| Vitamin E | Antioxidant | ❌ No | Partial | ✅ Moderate |
4. Usage Protocol for Raynaud's
| Parameter | Recommendation |
|---|---|
| Form | artisanal preparation (TRPV1-active gingerols) |
| Daily dose | 1–2 INTI shots |
| Optimal time | Morning + before cold exposure |
| Minimum duration | 6–8 weeks |
| Combine | Ginkgo biloba, omega-3 (rheological synergy) |
| Caution | Anti-aggregant effect → caution with anticoagulants |
| Additional measures | Warm gloves, stop smoking (nicotine = vasoconstriction) |
❓ FAQ — Ginger & Raynaud's Syndrome
Does ginger really warm the hands?
Yes — TRPV1 → CGRP activation causes measurable peripheral vasodilation. Infrared thermography shows +1.2–1.8°C finger temperature within 45 min after intake.
Primary vs. secondary Raynaud's?
Primary (idiopathic) responds better to natural approaches. In secondary Raynaud's (scleroderma), treatment of the underlying disease is paramount; ginger can be complementary.
Can I take ginger with calcium channel blockers (nifedipine)?
CYP3A4 interaction possible with high doses. At normal doses (1–2 shots/day), the risk is low. Consult a doctor if using calcium channel blockers.
Is summer use beneficial?
Yes. Continuous use maintains Nrf2/NO endothelial protection and basal CGRP levels, which reduces winter attack frequency.
Made in Belgium for warm hands and feet, even in winter.
→ Discover INTI on inti-drink.com
Related articles
Further reading on related topics:
- ginger ginger-natural-headache-relief-alternative-medication-2026">migraine-trigeminal-cgrp-attack-prevention-gingerols">Ginger and migraine: trigeminal mechanisms, CGRP and attack prevention with gingerols
- Ginger & Interstitial Cystitis: NF-κB, TRPV1 and Bladder Inflammation (2025)
- Ginger & Dizziness: TRPV1, 5-HT3 and Vestibular System (2025)
- Ginger & Asthma: TRPA1, Bronchospasm and Airway Inflammation (2025)
- fibromyalgia-central-sensitization-substance-p-diffuse-pain-science">Ginger and fibromyalgia: central sensitization, substance P and diffuse pain — what does science say?
- Ginger for Winter Sports: Ski, Snowboard, Recovery & Cold
- Chronic Migraine: NF-kB, CGRP and Ginger — Mechanisms and Hope
- Migraine in Belgium: sugar, CGRP, TRPV1 and ginger (2025)